Oligodendroglioma Clinical Trials

A listing of Oligodendroglioma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 13 clinical trials
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)

A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.

trametinib
dabrafenib
  • 492 views
  • 29 Oct, 2022
  • 15 locations
Phase II Trial of Treatment Intensification for IDH Wildtype, Non-Histological Glioblastoma, Gliomas (IDH Wildtype Lower Grade Glioma Treatment Intensification)

This phase II trial studies how well temozolomide and radiation therapy work in treating patients with IDH wildtype historically lower grade gliomas or non-histological molecular glioblastomas. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. Drugs used …

anaplastic oligodendroglioma
oligodendroglioma, anaplastic
astrocytoma
blood urea nitrogen
anaplastic astrocytoma
  • 0 views
  • 25 Oct, 2022
  • 1 location
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Patients will receive a vaccine called SurVaxM on this study. While vaccines are usually thought of as ways to prevent diseases, vaccines can also be used to treat cancer. SurVaxM is designed to tell the body's immune system to look for tumor cells that express a protein called survivin and …

sargramostim
diffuse intrinsic pontine glioma
cancer
montanide isa-51
tumor cells
  • 0 views
  • 07 Oct, 2022
  • 4 locations
Phase 2 Study to Evaluate the Clinical Efficacy and Safety of Sintilimab Plus Low-dose Bevacizumab in Patients With Oligodendroglioma of Different Relapse Stages

dosage schedule in adult (≥ 18 years) participants with a clinical relapse or circulating tumor DNA (ctDNA)-level relapse of Oligodendroglioma(WHO III). This study has three non-comparative study

oligodendroglioma
MRI
bevacizumab
karnofsky performance status
  • 0 views
  • 17 Oct, 2022
  • 1 location
Improvement of Functional Outcome for Patients With Newly Diagnosed Grade II or III Glioma With Co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 Trial (ImproveCodel)

Oligodendrogliomas in the novel edition of the Central Nervous System (CNS) World Health Organization (WHO) classification are now molecularly defined by isocitrate dehydrogenase (IDH)1 or IDH2

IDH2
immunohistochemistry
vincristine
temozolomide
tumor progression
  • 0 views
  • 19 Oct, 2022
  • 17 locations
Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas

This clinical trial studies the side effects of temporally-modulated pulsed radiation therapy (TMPRT) in patients with IDH-mutant gliomas who have previously received radiation therapy to the brain. TMPRT is a radiation technique in which radiation is delivered in multiple small doses on a specific timed interval, instead of delivering one …

karnofsky performance status
recurrent tumor
astrocytoma
oligodendroglioma
  • 0 views
  • 04 Oct, 2022
  • 1 location
Phase II Trial of Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory Glioblastoma Multiforme, Anaplastic Astrocytoma, and Anaplastic Oligoastrocytoma

Primary brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with median survival at approximately 12 months. Glioma is the most common form of primary brain cancer, …

growth factor
astrocytoma
glioblastoma multiforme
cancer
anaplastic astrocytoma
  • 283 views
  • 28 Oct, 2022
  • 1 location
PARP Inhibition for Gliomas (PI-4G or π4g)

The purpose of this study is to determine what effects (good and bad) niraparib has on patients with recurrent brain cancer.

  • 0 views
  • 04 Oct, 2022
  • 1 location
Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma

This randomized phase II clinical trial studies the side effects and how well proton beam or intensity-modulated radiation therapy works in preserving brain function in patients with IDH mutant grade II or III glioma. Proton beam radiation therapy uses tiny charged particles to deliver radiation directly to the tumor and …

blood transfusion
neutrophil count
astrocytoma
step 2
flair
  • 73 views
  • 04 Oct, 2022
  • 14 locations
Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma

Background The brain is separated from the rest of the blood stream by the blood-brain barrier. This is like a filter that protects the brain. But is also a challenge when medicines need to get into the brain. Researchers want to give the new drug LB100 to people before brain …

recurrent disease
astrocytoma
renal function test
glioblastoma multiforme
recurrent glioblastoma
  • 22 views
  • 25 Oct, 2022
  • 1 location